drug
(atezolizumab + hyaluronidase (human recombinant))
Marketedupdated 3mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
NSCLCMelanoma
all catalysts(5)
approval · 5
Sep 12, 2024
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
Aug 18, 2025
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
Oct 2, 2025
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
Nov 17, 2025
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
Nov 24, 2025
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that